menu
    • menu
    [{"orgOrder":0,"company":"UCLA Jonsson Comprehensive Cancer Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"UCLA Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"UCLA Jonsson Comprehensive Cancer Center \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCLA Jonsson Comprehensive Cancer Center \/ Inapplicable"},{"orgOrder":0,"company":"UCLA Jonsson Comprehensive Cancer Center","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berzosertib","moa":"Serine-protein kinase ATR","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"UCLA Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"UCLA Jonsson Comprehensive Cancer Center \/ UCLA Jonsson Comprehensive Cancer Center","highestDevelopmentStatusID":"1","companyTruncated":"UCLA Jonsson Comprehensive Cancer Center \/ UCLA Jonsson Comprehensive Cancer Center"},{"orgOrder":0,"company":"UCLA Jonsson Comprehensive Cancer Center","sponsor":"Ananda Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"UCLA Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Dry Powder","sponsorNew":"UCLA Jonsson Comprehensive Cancer Center \/ UCLA Jonsson Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"UCLA Jonsson Comprehensive Cancer Center \/ UCLA Jonsson Comprehensive Cancer Center"},{"orgOrder":0,"company":"UCLA Jonsson Comprehensive Cancer Center","sponsor":"CancerVAX","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"UCLA Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCLA Jonsson Comprehensive Cancer Center \/ UCLA Jonsson Comprehensive Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"UCLA Jonsson Comprehensive Cancer Center \/ UCLA Jonsson Comprehensive Cancer Center"}]

    Find Clinical Drug Pipeline Developments & Deals by UCLA Jonsson Comprehensive Cancer Center

    Menu

    UCLA Jonsson Comprehensive Cancer Center

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            UCLA Jonsson Comprehensive Cancer Center

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed

                            UCLA Jonsson Comprehensive Cancer Center

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Recipient : Ananda Scientific

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ANANDA and UCLA Begin Trial of Nantheia ATL5 for Smoking Cessation

                            Details : Nantheia ATL5 is an investigational drug that combines cannabidiol with ANANDA’s proprietary Liquid Structure delivery technology, being developed for smoking cessation.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            October 22, 2024

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Recipient : Ananda Scientific

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            UCLA Jonsson Comprehensive Cancer Center

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed

                            UCLA Jonsson Comprehensive Cancer Center

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : CancerVAX

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CancerVAX Reports Positive Progress on Kids Cancer Immunotherapy Treatment

                            Details : CAR-T cells and bispecific antibodies targeting this protein biomarker. The findings of this work will create and evaluate new promising tools for recruiting and activating the patient’s own immune system to track and destroy Ewing sarcoma tumors.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 06, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : CancerVAX

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            UCLA Jonsson Comprehensive Cancer Center

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed

                            UCLA Jonsson Comprehensive Cancer Center

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Drug Combination “Breakthrough” Gives Longest-Ever Survival in Patients with Nonresectable Liver Cancer

                            Details : Atezolizumab is an immune checkpoint inhibitor drug, which helps the immune system hunt down and destroy cancer.

                            Product Name : Tecentriq

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            June 02, 2021

                            Lead Product(s) : Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            UCLA Jonsson Comprehensive Cancer Center

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed

                            UCLA Jonsson Comprehensive Cancer Center

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berzosertib

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Recipient : Merck Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Potential COVID-19 Treatment Identified in UCLA-Led Lab Study

                            Details : Berzosertib, which is licensed by Merck KGaA, Darmstadt, Germany, is being investigated in separate early- and mid-stage clinical trials in combination with chemotherapy as a possible treatment for small-cell lung cancer, ovarian cancer and other types o...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 24, 2021

                            Lead Product(s) : Berzosertib

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Merck Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth